X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://www.prnewswire.com/news-releases/ascletis-announces-positive-interim-data-from-the-phase-iib-expansion-cohort-of-asc22-envafolimab-for-chronic-hepatitis-b-functional-cure-301941562.html
https://www.prnewswire.com/news-releases/clinical-results-of-asc22-envafolimab-in-combination-with-chidamide-for-functional-cure-of-hiv-infection-presented-at-the-12th-ias-conference-on-hiv-science-301884101.html
https://www.globenewswire.com/news-release/2023/06/20/2691010/10391/en/TRACON-Pharmaceuticals-Announces-Positive-Results-Based-on-Ongoing-Double-Digit-Objective-Response-Rate-for-Single-Agent-Envafolimab-in-the-ENVASARC-Phase-2-Pivotal-Trial.html
https://www.prnewswire.com/news-releases/ascletis-announces-dosing-of-the-first-patient-in-the-phase-iib-expansion-cohort-of-asc22-envafolimab-for-chronic-hepatitis-b-functional-cure-301634508.html
https://www.clinicaltrialsarena.com/news/biocytogen-tracon-sarcoma-trial/
https://www.prnewswire.com/news-releases/ascletis-announced-first-subject-dosed-in-the-phase-ii-clinical-trial-of-asc22-envafolimab-for-immune-restoration-functional-cure-of-hiv-1-infection-301576749.html
https://www.prnewswire.com/news-releases/ascletis-subcutaneous-pd-l1-antibody-asc22-demonstrated-potential-of-functional-cure-of-chronic-hepatitis-b-as-42-9-of-patients-with-baseline-hbsag100-iuml-obtained-sustained-hbsag-loss-301575290.html
https://www.asiaone.com/business/ascletis-announces-us-ind-approval-asc22-envafolimab-immune-restorationfunctional-cure-hiv
https://www.prnewswire.com/news-releases/shanghai-public-health-clinical-center-initiated-functional-cure-study-of-anti-pd-l1-antibody-asc22-envafolimab-in-combination-with-chidamide-in-hiv-infected-patients-301481425.html
https://www.prnewswire.com/news-releases/ascletis-announces-us-ind-approval-of-oral-pd-l1-small-molecule-inhibitor-asc61-for-treatment-of-advanced-solid-tumors-301476172.html
https://www.prnewswire.com/news-releases/ascletis-announces-us-ind-approval-of-asc22-envafolimab-a-subcutaneously-administered-pd-l1-antibody-for-functional-cure-of-chronic-hepatitis-b-301461906.html
https://www.globenewswire.com/news-release/2021/12/27/2358037/10391/en/TRACON-Pharmaceuticals-Announces-Positive-Results-from-the-Independent-Data-Monitoring-Committee-Review-of-Interim-Safety-and-Efficacy-Data-from-the-Ongoing-ENVASARC-Pivotal-Trial.html
https://www.prnewswire.com/news-releases/clinical-studies-of-pd-l1-antibody-asc22-for-hbv-functional-cure-selected-for-inclusion-in-the-best-of-the-liver-meetings-summary-by-aasld-review-committee-301424737.html
https://www.prnewswire.com/news-releases/ascletis-announces-approval-of-phase-ii-clinical-trial-of-asc22-envafolimab-by-china-nmpa-for-immune-restorationfunctional-cure-of-hiv-1-infected-patients-301420068.html
https://www.prnewswire.com/news-releases/sustained-hepatitis-b-surface-antigen-loss-in-chronic-hepatitis-b-patients-with-subcutaneous-pd-l1-antibody-asc22-treatment-interim-results-of-phase-iib-study-301419147.html
https://www.prnewswire.com/news-releases/ascletis-and-suzhou-alphamab-expand-their-partnership-into-worldwide-license-agreement-for-asc22-envafolimab-to-treat-hepatitis-b-and-other-viral-diseases-301418129.html
https://www.prnewswire.com/news-releases/ascletis-announces-results-of-the-phase-iia-trial-of-asc22-envafolimab-in-patients-with-chronic-hepatitis-b-to-be-presented-in-oral-parallel-session-at-the-liver-meeting-2021-by-american-association-for-the-study-of-liver-disea-301396930.html
https://www.globenewswire.com/news-release/2021/06/29/2254710/0/en/TRACON-Pharmaceuticals-Announces-Orphan-Drug-Designation-for-Envafolimab-in-Soft-Tissue-Sarcoma.html
https://www.globenewswire.com/fr/news-release/2021/01/19/2160596/0/en/TRACON-Pharmaceuticals-Announces-Acceptance-of-the-Envafolimab-KN035-NDA-by-the-NMPA-in-China-for-Priority-Review.html
https://www.globenewswire.com/news-release/2020/12/30/2151712/0/en/TRACON-Pharmaceuticals-Announces-Acceptance-of-the-Envafolimab-KN035-NDA-by-the-NMPA-in-China-that-was-Submitted-by-its-Corporate-Partners-Alphamab-Oncology-and-3D-Medicines.html
https://www.globenewswire.com/news-release/2020/09/21/2096484/0/en/TRACON-Pharmaceuticals-Highlights-Updated-Envafolimab-Clinical-Results-in-MSI-H-dMMR-Colorectal-Cancer.html
https://www.globenewswire.com/news-release/2020/05/11/2031071/0/en/TRACON-Pharmaceuticals-Announces-Successful-Type-B-Meeting-with-FDA-for-Pivotal-Study-of-Envafolimab-in-Sarcoma.html
https://endpts.com/seeking-an-edge-in-the-global-i-o-race-alphamab-oncology-loads-up-100m-from-marquee-backers/
https://www.biospectrumasia.com/news/39/11867/alphamab-starts-phase-i-clinical-trial-in-australia.html
Market Place
Share 
